Gut microbiome-mediated bioactive ingredients and health benefits of medicinal and edible fermented products: A comprehensive review

This comprehensive narrative review examines how fermented foods and beverages — such as yogurt, kimchi, and kefir — generate bioactive compounds through microbial activity and how those compounds interact with the gut microbiome to produce measurable health benefits. Bacteria and yeasts involved in fermentation break down food substrates into 31 identified bioactives, including short-chain fatty acids (SCFAs), bioactive peptides, exopolysaccharides, and modified polyphenols, which are more bioavailable than their unfermented equivalents. These molecules act on the gut lining by reinforcing tight junctions and stimulating mucin production, effectively strengthening the intestinal barrier. They also modulate immune responses, dampen inflammatory signaling (via NF-κB inhibition and Nrf2 activation), and improve metabolic markers including blood glucose and lipid levels. Epidemiological and clinical data cited in the review link regular fermented food consumption to an 8–15% reduction in HbA1c in type 2 diabetes, 5–10% cholesterol lowering in cardiovascular disease contexts, and 20–35% fewer infections as a marker of immune resilience. The review also covers benefits for gut-brain axis signaling, irritable bowel syndrome symptom relief, and cancer prevention, particularly colorectal cancer with dose-response patterns noted. The authors conclude that while evidence is promising, standardization of products, ensuring microbial viability through processing, and long-term human trials remain critical unmet needs.

• Fermentation generates 31 identified bioactive compounds — including SCFAs, bioactive peptides, exopolysaccharides, and modified polyphenols — with enhanced bioavailability relative to unfermented food matrices.
• Regular consumption of fermented foods (notably yogurt, kimchi, kefir) is associated with 8–15% reductions in HbA1c in type 2 diabetes populations and 5–10% cholesterol lowering relevant to cardiovascular disease risk.
• Immune resilience data show 20–35% fewer infections linked to fermented food consumption, with mechanistic attribution to Toll-like receptor activation and T-cell differentiation modulation.
• Gut barrier integrity is reinforced through tight-junction upregulation and mucin production stimulated by fermentation-derived bioactives, directly implicating mucosal physiology in systemic health outcomes.
• Colorectal cancer risk reduction follows a dose-response pattern with fermented food intake, and neuroprotective effects including cognitive improvements are reported via gut-brain axis signaling.

This is a comprehensive narrative review synthesizing published epidemiological, clinical, and mechanistic literature on medicinal and edible fermented products. No primary data collection was performed; the authors aggregated findings across studies examining lactic acid bacteria, yeast, and mixed-consortium fermentation systems and their downstream microbiome-host interactions. The review covers molecular pathway data (tight-junction regulation, NF-κB/Nrf2 signaling, TLR activation), metabolic outcomes, and epidemiological associations across multiple disease endpoints. Specific inclusion/exclusion criteria for source studies and a formal PRISMA-style search protocol are not described, consistent with a narrative rather than systematic review design.

As a narrative review, this article is susceptible to selection bias in the studies cited and cannot establish causality between fermented food consumption and the reported health outcomes. The quantitative figures cited (e.g., 8–15% HbA1c reduction, 20–35% fewer infections) are drawn from heterogeneous studies with differing populations, products, doses, and follow-up durations, limiting direct comparability. Microbial viability through commercial processing, inter-individual microbiome variability, and lack of standardized fermented product definitions across studies are acknowledged as persistent confounders. The next critical experiments would be well-powered, long-term randomized controlled trials using standardized fermented products with multi-omics endpoints to move these associations toward mechanistic validation.

This review extends [§150] by providing a detailed inventory of the specific fermented food-derived bioactives — SCFAs, EPS, modified polyphenols — that operationalize the gut microbiota–immune regulatory axis that [§150] frames theoretically, particularly around NF-κB inhibition and T-cell differentiation. It parallels [§144], which similarly synthesizes molecular pathways and clinical applications of probiotics across intestinal, neurologic, and cardiometabolic domains, though the present review distinctively foregrounds the fermentation process itself as a bioactive-generating system rather than probiotic supplementation. The mucosal mechanisms described here — tight-junction upregulation, mucin production, and SCFA-mediated barrier reinforcement — directly complement findings in [§120], where Eubacterium rectale mitigates IBD via metabolic (glutamine) and NF-κB pathways, illustrating convergent microbial strategies for mucosal protection. The review also parallels [§155], which examines Saccharomyces boulardii's specific effects on intestinal barrier function, providing a single-organism contrast to the mixed-consortium, food-matrix perspective taken here. Connections to metabolic disease mechanisms align the review with [§148], which examines dietary starch intervention effects on dyslipidaemia and gut leakiness, reinforcing the broader theme that diet-microbiome-barrier interactions are central to cardiometabolic health.

• Molecular Pathways and Clinical Applications of Probiotics as Effective Supporters of Intestinal, Neurologic, and Cardiovascular Health: a Narrative Review
  Directly parallel scope — both synthesize molecular pathways and clinical outcomes of microbiome-modulating interventions across intestinal, neurological, and cardiometabolic domains, making side-by-side reading essential for distinguishing fermented food effects from probiotic supplementation effects.
• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Saccharomyces boulardii's intestinal barrier data offer a single-organism, mechanistically controlled counterpoint to the mixed-consortium fermented food effects described here, allowing readers to isolate yeast-specific contributions to barrier function.
• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Eubacterium rectale's mucosal protection via NF-κB and glutamine metabolism parallels the tight-junction and NF-κB inhibition mechanisms attributed to fermented food bioactives, enabling comparison of single-strain versus food-matrix approaches to mucosal repair.
• Dietary Intervention with Brown Top Millet Starch Ameliorates Dyslipidaemia and Gut Leakiness in High Fat Diet Fed Models
  Both articles examine diet-driven gut microbiome remodeling as a mechanism for improving metabolic outcomes and reducing gut leakiness, but the millet starch study provides a controlled dietary intervention design that contrasts with this review's broader narrative synthesis.
• Mechanism of FODMAP Restriction on FGID Patients
  FODMAP restriction represents an alternative dietary strategy targeting gut fermentation and microbiota composition in functional GI disorders, offering a mechanistic counterpoint to the pro-fermentation health narrative and directly relevant to the IBS symptom relief claims reviewed here.